EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops

Gerry George Mathew

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 21.11.2026

DOI: 10.1177/08968608261508817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, online erschienen am 21.11.2026. Verfasst von Gerry George Mathew. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycaemic assessment is particularly difficult in people treated with peritoneal dialysis (PD). Glycated haemoglobin loses accuracy and precision in advanced kidney disease, and continuous absorption of dialysate glucose creates a glycaemic load that intermittent capillary testing cannot capture. Continuous glucose monitoring (CGM) provides dense ambulatory interstitial glucose data, but PD-specific evidence remains small and heterogeneous. In the largest CGM cohort of people receiving maintenance dialysis, hyperglycaemia that was often not clinically evident was most prominent among those treated with PD. This narrative review appraises the analytical performance, clinical accuracy and practical limitations of CGM in PD and separates defensible conclusions from over-interpretation. Contemporary sensors have shown acceptable accuracy against laboratory references in small single-centre PD cohorts, including one of icodextrin-treated patients, but performance varies with device, calibration requirement, reference standard and dialysis modality, and both the magnitude and the direction of sensor error affect time-in-range metrics. The best-documented icodextrin hazard is maltose interference with non-glucose-specific blood glucose meters used for confirmation or calibration. Because glucose specificity is a property of each enzyme and sensor, and anuric patients receiving daily icodextrin have not been specifically studied, device-specific validation in this subgroup remains a safety prerequisite before sensor readings guide insulin dosing. CGM is a reasonable adjunct for selected patients, particularly when laboratory markers are discordant, but current data do not support prescriptive treatment algorithms or regulatory conclusions. Pragmatic multicentre accuracy studies, registries and trials using CGM-derived and patient-reported outcomes are realistic next steps.

Zitieren

APA

Mathew, G. G. (2026). Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608261508817

Vancouver

Mathew GG. Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2026. doi:10.1177/08968608261508817

BibTeX
@article{Mathew2026,
  author = {Mathew, Gerry George},
  title = {Continuous glucose monitoring in peritoneal dialysis: What the evidence supports and where it stops},
  journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
  year = {2026},
  doi = {10.1177/08968608261508817}
}
Kostenlos starten →